Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
about
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Drug conjugates—an emerging approach to treat breast cancer.Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
P2860
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Anti-cancer Antibody Trastuzum ...... n the Brain: an In-Vivo Study.
@en
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate
@nl
type
label
Anti-cancer Antibody Trastuzum ...... n the Brain: an In-Vivo Study.
@en
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate
@nl
prefLabel
Anti-cancer Antibody Trastuzum ...... n the Brain: an In-Vivo Study.
@en
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate
@nl
P2093
P2860
P1476
Anti-cancer Antibody Trastuzum ...... n the Brain: an In-Vivo Study.
@en
P2093
Chris E Adkins
Evelina Rubinchik
Mei Mei Tian
Mohamed Afroz
Mohamed Ismail Nounou
Paul R Lockman
Reinhard Gabathuler
Tim Vitalis
Tori B Terrell-Hall
P2860
P304
P356
10.1007/S11095-016-2015-0
P577
2016-08-15T00:00:00Z